Helus 公司 III 期试验:致幻剂 HLP003 联合用药改善抑郁症伴安全性疑问
STAT+: Helus’ psychedelic drug improved depression in study but faces safety questions
Helus Pharma 宣布其致幻剂候选药物 HLP003 在 III 期试验中对重度抑郁症患者产生显著疗效,但与标准抗抑郁药联用时出现严重不良事件,引发安全性质疑。试验方案为第 1 天给药一次,第 3 周再给药一次;6 周时 HLP003 组 MADRS 评分较基线下降 19.5 分,安慰剂组下降 11.9 分,12 周时分别下降 16.9 分和 9.9 分,组间差异均具统计学意义。
![]()
Elaine’s stories explore the boom in new obesity treatments, new drug payment models, the ways companies are affected by FDA changes, and the emerging psychedelics drug sector. She co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud. You can reach Elaine on Signal at elaineywchen.70.
A psychedelic drug candidate from Helus Pharma significantly helped people with major depression in a Phase 3 trial, the company said Monday, but a number of serious adverse events in the study raised questions about the safety of the treatment.
Participants took one dose of the drug, called HLP003, on the first day of the trial and a second dose three weeks later. Six weeks into the study, people taking the drug in addition to their standard antidepressants experienced a reduction of 19.5 points on a depression rating scale called the MADRS, while the placebo group had a 11.9-point reduction.
At 12 weeks, the effect was largely maintained, with the treatment group seeing a 16.9-point reduction and the placebo group experiencing a 9.9-point reduction. The differences between the two groups were all statistically significant.
STAT+ Exclusive Story
Already have an account? Log in

This article is exclusive to STAT+ subscribers
Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.
Already have an account? Log in
To read the rest of this story subscribe to STAT+.
来源:STAT 主站 · statnews.com